[literature-animal] Angiogenesis at injury sites via eNOS + VEGF upregulation and fibroblast migration; data are overwhelmingly animal (since ~1993) — only one weak human self-report study, so human effects may include placebo. — Huberman 00:19–00:27
[literature-animal] Croatian phase 1/2 enema trials (~80 mg) for ulcerative colitis (positive phase-2 signal, but full data unpublished — and nearly all BPC data come from one group). LD50 unknown; no animal carcinogen signal. US phase-2 hamstring trial reportedly underway. — Bakri 00:19–00:43
[educational] Human data is 3 tiny studies (interstitial cystitis 12 women/single dose; IV safety 2 people; retrospective knee 16 people) + a registered oral safety trial that was never published → no real human safety data. Bioavailability by route: subQ ~35–50%, oral ~20–35% (high for a peptide, acid-resistant), topical ~10%. — BPC-157 deep dive
[literature]First registered RCT (2026): NCT07437547 — SubQ BPC 157 once daily ×14 d vs placebo for acute hamstring strain (recruiting; no results). Upgrades the “phase-2 hamstring trial reportedly underway” anecdote to a registered controlled trial; a positive readout would be P0. — SOURCE-bpc157-hamstring-rct-nct07437547
Anecdotes
[anecdote] Used across thousands of patients as a broad anti-inflammatory (reduces stiffness/soreness, aids recovery; post-viral use during the pandemic). Observed to upregulate the GH receptor, so it pairs with GH-releasing peptides. Injected SubQ acts systemically — abdomen injection benefits distant joints. — Koniver 00:19–00:29
[anecdote] Identity/history: 15-aa fragment of the natural 40-kDa gastric BPC protein (Croatian group 1991; lineage to Pavlov’s gastric juices + Selye’s stress-adaptation). PDA (pentadeca arginate) = the same molecule sold to dodge the cat-2 ban. Strong gut-brain-axis effects (blunts Adderall; anhedonia reports; in mice eases intoxication/withdrawal); oral BPC acts locally, not systemically. — Bakri 00:07–00:51
[anecdote-bb] Bodybuilding panel rate BPC-157 + TB-500 the only peptides ‘that actually do something’ (A-tier, healing); reiterate GH-receptor upregulation (pair with GH for tendon repair) and bidirectional angiogenesis (regional downregulation → speculative anti-cancer nuance). A coach reports ~15 months oral BPC-157 (400–800 mcg) easing gut/gluten-exposure symptoms. — Anabolic Roundtable ~01:20–01:27
Physician protocols
[protocol] Start ~500 mcg/day, titrate up to ~5,000 mcg/day; 5 days on / 2 off. Oral for gut-localised issues (IBD, IBS, leaky gut); SubQ (30–31g insulin needle) often better even for the gut. Can be injected into tendons with PRP/PRF. — Koniver 00:20–00:28
[protocol] 300–500 mcg SubQ, 2–3×/week (up to 5); ~8 weeks on, 8–10 weeks off; minimal effective dose, avoid continuous daily use. LD50 ~2 g/kg — not a license to dose high. — Huberman 00:29–00:34
[protocol] Bakri used gram-range local doses for a grade-2 triceps tear (~3–4-wk healing) and argues common microgram doses may be sub-therapeutic in humans. Anecdote; human dose not established. — Bakri 00:54–00:55
[protocol] vs TB-500/TB4: BPC wins for musculoskeletal (more/stronger data, lower cancer risk) → BPC alone for minor chronic injuries, add TB4 only if healing plateaus; for acute major injuries / post-surgery / stroke / major TBI, start BPC + TB4 together (synergistic — BPC via NO/VEGF angiogenesis, TB4 via actin/structure). — TB500 deep dive
[protocol]subQ for musculoskeletal/systemic; oral (arginate salt) preferred for gut (direct mucosal contact). No need to inject locally (rapid systemic uptake). Theoretical HED ~181 mcg/day subQ; anecdotal 250–500 mcg subQ / 500–1,000 mcg oral, start low. 4–8 weeks on (or until healed), 4–8 off; not indefinite. — BPC-157 deep dive
Practical notes
[warning]Tumor-growth risk: upregulates VEGF (opposite of the anti-cancer VEGF-inhibitor Avastin) plus GH receptors → may feed/accelerate tumors and neovascular eye disease. Avoid with any cancer/tumor concern; monitor health metrics. — Huberman 00:30–00:35, 01:03
[educational] Sourcing: demand a batch-specific COA — HPLC/MS identity & purity (>99%; Janoshik), USP<85> endotoxin, USP<71> sterility; oral needs purity/identity only. A regulated compounding pharmacy beats any research-use-only source. — BPC-157 deep dive
[regulatory]US status shifting (2026): BPC-157 was removed from FDA Category 2 (Feb 2026) and is the lead item on the FDA PCAC 503A agenda for July 23 2026 — FDA’s evaluated use is ulcerative colitis (matching the Croatian enema phase-1/2 signal above), not athletic recovery. Advisory/non-binding; a favorable vote + rulemaking would open a legal compounding-pharmacy pathway. Not FDA-approved. — SOURCE-fda-pcac-503a-peptide-review-2026